Ponatinib

t(9;22)

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Dormant

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

35 Active assets in the t(9;22) cohort.

Asset / Sponsor	Phase	Rating
Nilotinib The University of Hong Kong	Phase 2	BBB
Blinatumomab Novartis Pharmaceuticals	Phase 3	BBB
Cytosin-Arabinosid Novartis Pharmaceuticals	Phase 3	BBB
METHOTREXATE Novartis Pharmaceuticals	Phase 3	BB
Imatinib The University of Hong Kong	Phase 3	BB

View all 50 →

Same molecule, other indications

Ponatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative ·

66 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

65 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.